NEW YORK (GenomeWeb News) – Quest Diagnostics today reported that second-quarter revenues were essentially flat compared to a year ago.

For the three months ended June 30, revenues inched up .5 percent year over year to $1.91 billion, up from $1.90 billion, missing Wall Street estimates of $1.94 billion.

Clinical testing revenues during the quarter inched up .7 percent, Quest said.

SG&A spending was down 5 percent to $440.8 million from $462.8 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.